Introduction
T he American Institute of Ultrasound in Medicine (AIUM) is a multidisciplinary association dedicated to advancing the safe and effective use of ultrasound (US) in medicine through professional and public education, research, development of clinical practice parameters, and accreditation of practices performing US examinations.
The AIUM Practice Parameter for the Performance of Contrast-Enhanced Ultrasound Examinations was developed by the AIUM in collaboration with other organizations whose members use US for performing this examination(s) (see "Acknowledgments"). Recommendations for personnel requirements, the request for the examination, documentation, quality assurance, and safety may vary among the organizations and may be addressed by each separately.
This Practice Parameter is intended to provide the medical US community with recommendations for the performance and recording of high-quality US examinations. The parameter reflects what the AIUM considers the appropriate criteria for this type of US examination but is not intended to establish a legal standard of care. Examinations performed in this specialty area are expected to follow the parameter with recognition that deviations may occur depending on the clinical situation.
Indications
Indications for contrast-enhanced ultrasound (CEUS) are based on the current literature recommendations and clinical practice standards.
Contrast-enhanced ultrasound is safe for patients with contraindications to computed tomography (CT) or magnetic resonance imaging (MRI), such as pacemakers, allergies to gadolinium-based or iodinated contrast material, claustrophobia, immobility, or metal implants. Because of its lack of ionizing radiation and ease of performance without sedation, CEUS should be considered as a useful problem-solving tool and as an indicated first-line imaging modality in select settings as indicated below. 
Qualifications and Responsibilities of Personnel
Physicians (and other providers if applicable) interpreting or performing this type of US examination should meet the specified AIUM Training Guidelines in accordance with AIUM accreditation policies. Sonographers performing the US examination should be appropriately credentialed in the specialty area in accordance with AIUM accreditation policies.
Request for the Examination
The written or electronic request for a US examination must originate from a physician or other appropriately licensed health care provider or under the provider's direction. The clinical information provided should allow for the performance and interpretation of the appropriate US examination and should be consistent with relevant legal and local health care facility requirements.
Specifications of the Examination
Contrast Dose: In adults, the standard dose for most abdominal applications is 2.4 mL of sulfur hexafluoride lipid microsphere (SHLM) contrast (eg, Lumason; Bracco Diagnostics, Inc, Monroe Township, NJ). In children, the dose is 0.03 mL/kg up to a maximum of 2.4 mL per injection. Intravascular administration of up to 5 mL of SHLM contrast (Lumason) in a single session is approved by the Food and Drug Administration (FDA).
The standard dose of perflutren lipid microsphere (PLM) contrast (eg, Definity; Lantheus Medical Imaging, North Billerica, MA) is 10 μL/kg. The standard dose of perflutren protein microsphere (PPM) contrast (eg, Optison; GE Healthcare, Princeton, NJ) is 0.5 mL. Additional 0.5-mL doses may be given to improve characterization of a finding or overcome artifacts encountered during the initial injection.
Summary of Scanning Protocols 
Equipment Specifications
The depth of penetration and image clarity may be reduced by low-mechanical index (MI) imaging.
However, users should be aware that microbubble destruction can lead to artifactual or pseudo washout.
Image Acquisition
All CEUS studies should be performed on a machine with contrast imaging capability and a dualdisplay mode. Each vendor has different proprietary methods for optimal detection and display of CEUS. Regardless of the vendor, the modality and instrument settings that optimize visualization of contrast and opacification of vascular structures should be used. Most of these techniques use a real-time low-MI technique, usually less than 0.3 for continuous imaging. A high-MI mode may be chosen for rapid bubble destruction in the field of view to evaluate microbubble replenishment. The targeted lesion should be imaged with B-mode before the contrast study.
Contrast agent detection relies on harmonic imaging, and fundamental (nonharmonic) imaging should be avoided. Suppression of the background tissue signal by phase/amplitude modulation and harmonic techniques can increase the sensitivity of the machine to the CEUS signal, but strongly reflective structures may still create artifacts despite background suppression. Likewise, high doses of contrast may limit visualization of deeper structures; therefore, proper dosing of contrast is important.
Gain settings should be adjusted to reduce signals from background structures before contrast injection. The scan plane should be selected to avoid overlying shadowing structures. The focal zone is typically placed at the deepest portions of the region of concern (organ or lesion). For deeper lesions, a lower frequency is preferred for depth penetration and an optimized microbubble signal. If a higher frequency is selected, an increased volume of contrast may be necessary to achieve adequate contrast enhancement display, since the microbubble signal is higher at typical lower transducer frequencies, and a higher frequency may also result in faster loss of the microbubble volume because of bubble destruction.
Quality and Safety
Policies and procedures related to quality assurance and improvement, safety, infection control, and equipment performance monitoring should be developed and implemented in accordance with the AIUM Standards and Guidelines for the Accreditation of Ultrasound Practices.
ALARA (As Low as Reasonably Achievable) Principle
The potential benefits and risks of each examination should be considered. The ALARA principle should be observed for factors that affect the acoustical output and by considering the transducer dwell time and total scanning time. Further details on ALARA may be found in the current AIUM publication Medical Ultrasound Safety.
Intravascular Administration
Mild physiologic adverse reactions include nausea and vomiting, taste alteration, headache, vertigo, flushing, and rash. These have an incidence of about 5% 15 and resolve spontaneously without lasting effects. Intra-arterial administration is contraindicated.
Ultrasound contrast agents (UCAs) are not contraindicated in patients with compromised renal function as they are not excreted by the kidneys. No blood tests are needed prior to administration.
Anaphylactoid (allergic-like) reactions
Ultrasound contrast agents carry an FDA black box warning and are contraindicated in patients with a history of allergy to the agent or its constituent gas or shell.
Hypersensitivity events are due to anaphylactoid (allergic-like) reactions to the gas or shell. Anaphylactoid reactions include hypotension with tachycardia, bronchospasm, urticaria, and pruritus. The incidence of serious anaphylactoid reactions is 0.006% to 0.01%, 16, 17 which is comparable to gadolinium-based contrast agents and lower than that for iodinated contrast agents. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions. A rate of 0.001% has been reported for life-threatening anaphylactoid reactions, less than the rate for CT or MRI contrast agents. 18 In most cases, hypersensitivity events occur within a few minutes of injection. Resuscitation equipment and trained personnel should be available when UCAs are administered. Contrast reactions should be managed according to the ACR Manual on Contrast Media Version 10.3 19 and the ACR-SPR Practice Parameter for the Use of Intravascular Contrast Media. 20 Ultrasound contrast agents have a similar safety profile in children. [21] [22] [23] 
Intravesical and intracavitary administration
Mild physiologic adverse events during intravesical administration of UCAs in children have been reported in 0.8% to 3.8% of cases and are thought to be primarily related to bladder catheterization and not the UCA. 24, 25 Intracavitary administration of UCAs has not been associated with specific complications.
Pregnancy
There have been no studies of UCAs in pregnant patients for SHLM contrast or PLM contrast. Animal studies have shown no harm to the fetus at doses of SHLM contrast up to 8 to 17 times the human dose based on the body surface area. 26 There are no studies on PPM contrast in pregnant humans, but teratogenic effects have been demonstrated in animal studies. The FDA recommends that PPM contrast be used in pregnancy only if the benefit outweighs the risk. 27 
Breastfeeding
There are no data on the presence of UCAs in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's need for UCAs and any potential adverse effects on the breastfed infant from UCAs or from the underlying maternal condition. Milk can be pumped and discarded within 24 hours of contrast administration as a precautionary measure.
Bioeffects of bubble fragmentation
Ultrasound pulses at moderate and high MIs result in substantial microbubble oscillation and fragmentation, which are referred to as stable and inertial cavitation, respectively. 28 This microbubble oscillation can have a range of biological effects under certain conditions, ranging from short-term mild changes in cellular permeability at moderate MIs [29] [30] [31] to hemolysis and capillary endothelial injury at higher MIs. [32] [33] [34] The magnitude of cavitation is proportional to the US amplitude 35 and inversely proportional to the frequency.
There have been reports of ventricular arrhythmias in echocardiography after imaging protocols that result in microbubble fragmentation when a high MI is applied. 36 However, no evidence of clinical bioeffects from cavitation during abdominal CEUS examinations have been found in humans at clinically relevant doses of contrast, and no cellular injury has been seen with CEUS examinations performed at the low power setting used in nondestructive imaging. However, given the evidence of bioeffects and that therapeutic applications of microbubbles are used with acoustic parameter ranges that have some overlap with diagnostic imaging parameters, microbubble insonation at moderate and high MIs should be used cautiously. The AIUM recommends that practitioners be aware of the MI used for any study, with an MI of 0.4 as a threshold value for bioeffects 37 :
"Induction of premature ventricular contractions, microvascular leakage with petechiae, glomerular capillary hemorrhage, and local cell killing in mammalian tissue in vivo have been reported and independently confirmed for diagnostic ultrasound exposure with a mechanical index (MI) above about 0.4 and a gas body contrast agent present in the circulation."
"Although the medical significance of such microscale bioeffects is uncertain, minimizing the potential for such effects represents prudent use of diagnostic ultrasound. In general, for imaging with contrast agents at an MI above 0.4, practitioners should use the minimal agent dose, MI, and examination time consistent with efficacious acquisition of diagnostic information."
Thus, an MI of greater than 0.4 for clearance pulses should be used sparingly and in accordance with the ALARA principle. Without a clearance pulse, contrast will usually be eliminated spontaneously from the circulation within 15 minutes.
Clinical CEUS examinations should generally be performed with a low MI of between 0.2 and 0.4.
PPM contrast contains human albumin, a derivative of human blood, and may confer a theoretical risk of viral or prion infection; additionally, it may not be used in patients with religious or ethical objections to the intravascular receipt of human blood products.
Infection Control
Transducer preparation, cleaning, and disinfection should follow manufacturer recommendations and be consistent with the AIUM Guidelines for Cleaning and Preparing External-and Internal-Use Ultrasound Transducers Between Patients, Safe Handling, and Use of Ultrasound Coupling Gel.
Equipment Performance Monitoring
Monitoring protocols for equipment performance should be developed and implemented in accordance with the AIUM Standards and Guidelines for the Accreditation of Ultrasound Practices.
